Items where authors include "Cook, G."

Article

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Agarwal, G., Moore, S., Sadler, R. et al. (21 more authors) (2024) Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma. Haematologica. ISSN 0390-6078

de Tute, R.M., Cook, G. orcid.org/0000-0003-1717-0412, Cairns, D.A. orcid.org/0000-0002-2338-0179 et al. (12 more authors) (2024) Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial. Bone Marrow Transplantation. ISSN 0268-3369

Keaveney, S. orcid.org/0000-0001-7715-0750, Dragan, A., Rata, M. et al. (25 more authors) (2023) Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma study. Insights into Imaging, 14 (1). 170.

Abani, O., Abbas, A., Abbas, F. et al. (7989 more authors) (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Diabetes & Endocrinology. ISSN 2213-8587

Chandler, T. orcid.org/0009-0001-1899-7510, Parrish, C., Karakantza, M. et al. (4 more authors) (2023) A comparison of peripheral blood stem cell collection outcomes for multiple myeloma; mobilization matters in the era of IMiD induction. EJHaem, 4 (3). pp. 625-630. ISSN 2688-6146

Barnes, E. orcid.org/0000-0002-0860-0831, Goodyear, C.S. orcid.org/0000-0001-5926-5941, Willicombe, M. orcid.org/0000-0002-6404-0584 et al. (154 more authors) (2023) SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nature Medicine. ISSN 1078-8956

Barnes, E. orcid.org/0000-0002-0860-0831, Goodyear, C.S. orcid.org/0000-0001-5926-5941, Willicombe, M. orcid.org/0000-0002-6404-0584 et al. (154 more authors) (2023) SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nature Medicine, 29 (7). pp. 1760-1774. ISSN 1078-8956

Abani, O., Abbas, A., Abbas, F. et al. (8104 more authors) (2023) Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. ISSN 0140-6736

Twumasi, C. orcid.org/0000-0001-6817-8356, Moore, S. orcid.org/0000-0003-1380-1934, Sadler, R. orcid.org/0000-0003-2250-670X et al. (20 more authors) (2023) Determinants of durable humoral and T cell immunity in myeloma patients following <scp>COVID</scp>‐19 vaccination. European Journal of Haematology. ISSN 0902-4441

Snowden, J.A. orcid.org/0000-0001-6819-3476, Ahmedzai, S.H., Cox, A. orcid.org/0000-0002-5138-1099 et al. (9 more authors) (2022) Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study. Bone Marrow Transplantation, 57 (10). pp. 1507-1513. ISSN 0268-3369

Hough, R., Lopes, A., Patrick, P. et al. (14 more authors) (2022) Primary graft failure, but not relapse, may be identified by early chimerism following double cord blood unit transplantation. Blood Advances, 6 (7). pp. 2414-2426. ISSN 2473-9529

Müller, L.M.E., Migneco, G., Scott, G.B. et al. (17 more authors) (2021) Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer, 9 (3). e001803. ISSN 2051-1426

Jackson, G.H., Pawlyn, C., Cairns, D.A. et al. (20 more authors) (2021) Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLOS Medicine, 18 (1). e1003454. ISSN 1549-1277

Ahmedzai, S.H., Snowden, J.A. orcid.org/0000-0001-6819-3476, Ashcroft, A.J. et al. (19 more authors) (2019) Patient-reported outcome results from the open-label, randomized phase III myeloma X trial evaluating salvage autologous stem-cell transplantation in relapsed multiple myeloma. Journal of Clinical Oncology, 37 (19). pp. 1617-1628. ISSN 0732-183X

Striha, A., Ashcroft, A.J., Hockaday, A. et al. (12 more authors) (2018) The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Trials, 19. 169. ISSN 1745-6215

Cook, G., Ashcroft, A.J., Cairns, D.A. et al. (17 more authors) (2016) The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol, 3 (7). e340-e351.

Parrish, C., Morris, C.T.C.M., Williams, C.D. et al. (13 more authors) (2016) Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. Biology of Blood and Marrow Transplantation, 22 (6). pp. 1009-1016. ISSN 1083-8791

Proceedings Paper

Cook, G., Ashcroft, A.J., Senior, E.R. et al. (16 more authors) (2023) Ixazomib-based consolidation and maintenance prolongs progression-free survival after salvage autologous stem cell transplantation (sASCT): Results from interim analysis of UK-MRA myeloma XII (ACCoRD). In: Blood. 65th ASH Annual Meeting, 09-12 Dec 2023, San Diego, California, USA. American Society of Hematology , p. 783.

Mueller, L.M.E., Parrish, C., Migneco, G. et al. (6 more authors) (2017) Evaluating the contribution of anti-myeloma immunity for the efficacy of oncolytic reovirus therapy. In: Clinical Cancer Research. Second AACR Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies, 06-09 May 2017, Boston, MA. American Association for Cancer Research , p. 18.

Jackson, G.H., Davies, F.E., Pawlyn, C. et al. (18 more authors) (2016) Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .

Pawlyn, C., Davies, F.E., Kaiser, M.F. et al. (18 more authors) (2016) Primary IMiD refractory myeloma; results from 3894 patients treated in the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .

Jackson, G.H., Davies, F.E., Pawlyn, C. et al. (18 more authors) (2016) Response adapted induction treatment improves outcomes for myeloma patients; results of the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .